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Abstract
Background: Despite the important role of adiponectin in regulating general metabolic homeostasis, analysis of
genetic determinants of adiponectin and the related cardio-metabolic traits in African American population has
been limited and inconsistent.
Considering the high genetic admixture of African Americans and thus the important population stratification that
may confound the genetic-trait associations, the objective of this work was to perform a comprehensive analysis
of the associations between ADIPOQ variants and adiponectin levels and obesity phenotypes in a large African
American population from the Jackson Heart Study (JHS) cohort.
Methods: Genotype data was available for 2968 JHS participants (1131men; 1837women). Single Nucleotide
Polymorphisms (SNPs) were selected by a Tag-SNP Approach and literature review. The genotype imputation was
performed using IMPUTE2 software and reference phased data from the 1000G project. PLINK software was used
for the genetic analysis. Plasma specimens were analyzed by ELISA for adiponectin levels. All analyses were
controlled for population stratification assessed by Individual Proportions of European Ancestry (PEA) estimates
calculated in HAPMIX using ancestry informative markers (AIMs).
Results: We found a gender-dependent association of some ADIPOQ variants and adiponectin levels. In women
four of the studied polymorphisms (rs6444174, rs16861205, rs1403697, rs7641507) were associated with adiponectin
levels after Bonferroni correction and controlling for the percentage of PEA, age, annual household income and
smoking. These results were consistent with the haplotype analysis. The association between the rs12495941 variant
and obesity is modulated by the PEA, so that the relationship between the G allele and a higher incidence of
obesity was present in those individuals within the lower PEA group. In addition we found an effect modification
of obesity on the association between the ADIPOQ rs6444174 SNP and BMI so that the presence of the T allele was
negatively and significantly associated with BMI only in participants with a normal weight.
Conclusions: In this large African American cohort, ADIPOQ variants were associated with adiponectin levels in a
gender-dependent manner and the relationship of some of these variants with obesity and BMI was modulated by the
PEA and obesity status respectively. This suggests that the effects of these polymorphisms on adiponectin and obesity
phenotypes are subject to a strong interaction with genetic and environmental factors in African American population.
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Background
In the last decade obesity has reached epidemic propor-
tions affecting one-third of the adult U.S. population
and is considered a major risk factor for development of
Type 2 Diabetes Mellitus (DM2), hyperlipidemia and
hypertension. All these disorders cluster together in
what we know today as the Metabolic Syndrome. How-
ever, in the U.S the obesity epidemic disproportionately
affects certain racial/ethnic minorities and it is generally
known that the prevalence of obesity varies widely by
ancestry, especially in African American women who
also display a more severe metabolic profile related to
the presence of obesity [1].
Adiponectin is an adipose tissue-specific hormone that
is responsible for increasing energy expenditure and
lipid catabolism as well as enhancing fatty acid oxidation
and insulin sensitivity [2]. In contrast to most other
adipocytokines, adiponectin appears in decreased con-
centrations in obese subjects [3]. Consequently, it is con-
sidered to be a protective factor for cardio metabolic
alterations [4] and has been proposed as a potential bio-
marker for therapeutic intervention for obesity, diabetes,
and other cardiovascular disorders [5]. African Americans
present lower serum adiponectin levels independent of
their body mass index (BMI) [6–8] and higher prevalence
of obesity with a more severe phenotype related to meta-
bolic alterations compared to Caucasians and other ethnic
groups.
Plasma adiponectin levels are highly heritable ranging
from 40 to 70 % [9, 10] and have been associated with
different genetic loci [11]. However the adiponectin gene
(ADIPOQ) located at position 3q27, remains the main
genetic determinant of plasma adiponectin levels [12].
The ADIPOQ gene spans 1.579 kb and contains 3 exons.
The translation start point is located in exon 2 [13]. Sev-
eral single nucleotide polymorphisms (SNPs) located in
the ADIPOQ gene have been associated with adiponectin
serum levels [13], body adiposity [14] and metabolic alter-
ations [15, 16], making this gene a candidate for obesity
and metabolic syndrome associated traits. However, a
limited number of studies that addressed the study of gen-
etic variants in the ADIPOQ gene in relation to adiponec-
tin levels and obesity phenotypes in African Americans
[16, 17], yielded conflicting results mainly because of small
sample size [17], inclusion of only one gender in the ana-
lysis [7], or the confounding effect of an unadjusted popu-
lation structure [18].
In the present study we tested the genetic association
of SNPs in ADIPOQ with obesity indexes (BMI, body fat
content, waist (WC) and hip circumferences (HC)) and
serum adiponectin levels in African Americans from the
Jackson Heart Study (JHS) with adjustment for popula-
tion structure using a dense panel of ancestry inform-
ative markers (AIMs).
Research design and methods
Study participants
The JHS is a single-site, prospective cohort study of risk
factors and causes of heart disease in adult African
Americans. A convenience sample of 5,301 self-reported
African Americans, aged 21–94 years, residing in three
adjacent counties in the Jackson, MS metropolitan area
were recruited, interviewed and examined by certified
technicians according to standardized protocols at a
baseline exam visit (2000–2004) [19, 20]. The clinic visit
included physical examination, anthropometry, survey of
medical history and of cardiovascular risk factors and
collection of blood and urine for biological variables.
Two subsequent examinations were conducted in 2005–
2008 and 2009–2013. The data for this study includes a
total of 2934 unrelated participants (1130 men and 1834
women) who had ADIPOQ SNPs genotyping information
and adiponectin measurements conducted on serum spec-
imens collected at baseline, and who underwent multi-
detector computed tomography (CT) measurements for
visceral adiposity between 2007 and 2009 during the sec-
ond JHS examination (JHS Exam 2). Written consent was
obtained from each participant at the inception of the
study. The study protocol was approved by the Institu-
tional Review Boards of the National Institutes of Health
and the participating JHS institutions_–including the
Tougaloo College, the Jackson State University and the
University of Mississippi Medical Center.
Biochemical and anthropometric measurements
Adiponectin measurement was derived from venous
blood samples drawn from each participant at baseline
visit after at least 8 h of fasting. Vials of serum were
stored at the JHS central repository in Minneapolis, MN,
at −80 °C until assayed. Adiponectin concentration was
measured in 2008–2012 as total plasma adiponectin by
an ELISA system (R&D Systems; Minneapolis, MN,
USA) [19, 21]. The inter-assay coefficient of variation
was 8.8 %. No biological degrading has been described
using stored specimens, indicating a high validity for
measurement [22].
For anthropometric variables, weight was measured on
a balance scale, in light clothing, without shoes, and re-
corded to the nearest 0.5 kg. BMI was calculated as weight
in kilograms divided by height in square meters. Over-
weight/obesity status was assessed based on BMI: [21]
individuals with BMI < 25 kg/m2 were considered of
normal weight (NW), individuals with BMI ≥ 25 kg/m2
and < 30 kg/m2 were considered overweight (OW), and
those with BMI ≥ 30 kg/m2 were considered obese. Waist
circumference (WC) was measured at the level of the um-
bilicus using anthropometric tape; hip circumference
(HC) was measured at the level of the widest circum-
ference over the greater trochanter. The measurements
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were recorded to the nearest centimeter upon the end of
exhalation. Body fat composition (expressed as total fat
mass (kg), and percent of body fat (%) were assessed using
a Tanita (Arlington Heights, IL, USA) TNF 300A im-
pedance body composition analyzer. The research CT
protocol for abdominal adipose tissue (VAT) and subcuta-
neous adipose tissue (SAT) measurements has been re-
ported previously [23]. Briefly, the CT images included
scout images, one ECG gated series of the entire heart,
and a series through the lower abdomen detected by com-
puted tomography system equipped with cardiac gating
(GE Healthcare Lightspeed 16 Pro, Milwaukee, WI, USA).
The acquired abdominal imaging slices covering the lower
abdomen from L3 to S1 were used for assessing VAT and
SAT. Briefly, 24 contiguous 2-mm-thick slices centered on
the lumbar disk space at L4–L5 were used for this ana-
lysis; 12 images before the center of the L4–L5 disk space
and 12 images after the disk space were used for quantifi-
cation of VAT and SAT. The abdominal muscular wall
was first manually traced, and the fat volumes in different
compartments were measured by semiautomatic segmen-
tation technique. Volume analysis software (Advantage
Windows; GE Healthcare, Waukesha, WI) was used to
segment and characterize each individual voxel as a tissue
attenuation of fat using a threshold range of −190 to −30
Hounsfield units. The VAT and SAT volumes were the
sum of VAT and SAT voxels over 24 slices. Participants
were excluded from the CT scan Exam if: 1) body weight
was greater than 350 lbs. (~160 kg); 2) pregnant or un-
known pregnancy status; 3) female participant < 40 years
of age; and 4) Male participant < 35 years of age. SAT was
defined as the total fat volume minus the visceral and
intramuscular fat volume. A total of 10 participants were
excluded based on these criteria.
Covariates
All covariate variables were collected at baseline and were
chosen because of their influence on adiponectin levels
and obesity measurements. Age was derived from date-
of-birth. Socioeconomic status (SES) was based on self-
reported annual household income and divided into three
categories (< $19,999, $20,000 – $49,999, > $50,000).
Smoking status was defined as current smokers and non-
smokers.
The proportion of European ancestry (PEA), an esti-
mate of the global proportion of individual European an-
cestry for our sample, was calculated using HAPMIX in
analyses supported by the CARe consortium [24–26].
Briefly, two datasets were used as reference populations:
1,178 European Americans samples and 756 samples of
African ancestry, represented here by the Yoruba (YRI)
from West Africa were used as parental samples to se-
lect the Ancestry Informative Markers (AIMs) from the
Affymetrix 6.0 genome-wide genotyping platform. After
removing related pairs and outlier samples determined
by quality control procedures using EIGENSOFT, a total
of 3,192 unlinked AIMs were obtained with allele fre-
quency between parental samples of at least 30 %. Then,
the HAPMIX program was used for inferring local an-
cestry (0, 1 or 2 European chromosomes) at each loca-
tion in the genome on the CARe samples, using phased
CEU and YRI haplotypes from HapMap3 as reference
[24]. HAPMIX was run in a mode that assigns European
or African ancestry to each allele, thus resolving the
local ancestry of each allele when both genotype and
local ancestry were heterozygous. Finally, the proportion
of the Global European Ancestry for each sample was
computed as the average of local ancestry estimates
across the genome (scaled to 0.0, 0.5 or 1.0). The pro-
portion of global European ancestry estimates for this
sample study had a median of 15.0 %.
SNP selection, genotyping and imputation
With the aim to investigate all the genetic variability in
ADIPOQ, we used a tag SNP approach for the selection of
the genetic variants in the study. This tagging approach
was applied on the entire set of common genetic variants
(including 5 kb upstream of the first exon and 5 kb down-
stream of the last exon of the gene), with minor allele
frequency (MAF) ≥1 % in Yoruba population (YBI) from
the International HapMap Project (release #24; http://
www.hapmap.org). Tagging SNPs were selected by the
Tagger algorithm available through Haploview [27], using
a pairwise SNP selection with a minimum r2 threshold of
0.8. This process resulted in a selection of 14 tagging SNPs
for ADIPOQ, with a mean r2 of the selected SNP of 0.969.
This selection therefore captures a very high degree (over
95 %) of the known common variability in this gene.
Additional relevant candidate SNPs were selected after
reviewing the literature, therefore providing a basis for
comparison with the JHS. For this study a total of 39 SNPs
in the ADIPOQ gene were selected.
For genotype imputation to infer ADIPOQ SNPs geno-
types in our study, IMPUTE2 software and reference phased
data from the 1000G project http://www.sph.umich.edu/
csg/yli/mach/download/1000G.2012-03-14.html) were used.
Details regarding the generation of the data can be found in
the Phase 1 article (The 1000 Genomes Project Consortium,
2012) [28]. Related individual were removed before the
genotype imputation.
SNPs quality control
SNP-level quality control metrics were applied prior to
downstream analyses. These were: call rate ≥ 95 %,
minor allele frequency (MAF) ≥ 1 %, Hardy-Weinberg
equilibrium (HWE) p > 10−3, and quality measures for
imputed SNPs (r2 ≥ 0.3).
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Additional file 1: Table S1 shows the characteristics,
minor allele frequencies and HWE p-values for the stud-
ied ADIPOQ SNPs. Of the 34 SNPs we excluded 2 from
the analysis due to low imputation quality (r2 < 0.3) Seven
SNPs were not consistent with HWE (p < 0.001) and
where removed for the analysis. In this cohort five variants
found to be nearly monomorphic with a MAF < 0.04
and thus excluded from further analysis (rs17366743,
rs17366568, rs17373414, rs17366499, rs2036373). After
the exclusion, a total of 24 SNPs analyzed in the JHS co-
hort. The minor allele frequencies for the analyzed SNPs
ranged from 5 to 45 %.
Statistical analysis
Statistical Package SAS version 9.3 (SAS Institute Inc.,
Cary, NC, USA) was used for descriptive statistical ana-
lysis. Participant characteristics were summarized with
means and standard deviations for continuous variables
and counts and percentages for categorical variables.
Power analyses for the tests of association were computed
using the QUANTO software (available at http://biostat-
s.usc.edu/software), using the minor allele frequencies and
mean values of serum adiponectin levels from the JHS
study and the effect sizes originally reported by previous
studies [29]. Assuming a p value of 0.001 and a power of
80 %, we will require 845 subjects in order to detect a 2 %
of variation in adiponectin levels. Hardy-Weinberg devia-
tions for each of the ADIPOQ SNPs included in the study
were tested by a chi-squared goodness of fit test.
Association analyses between the SNPs and the selected
variables were conducted in PLINK [30]. Association be-
tween ADIPOQ SNPs and continuous (BMI, WC, HC,
SAT, VAT) and categorical outcomes (obesity) were tested
by linear and logistic regression models under an additive
genetic model using age, gender, BMI, SES, and smoking
as covariates for model adjustment except in the analysis
with BMI. To control for population stratification we in-
clude the Percentage of European Ancestry (PEA) as a
continuous variable into the models.
Adiponectin and BMI values were log transformed to
obtain better approximations of the normal distribution
prior to analysis. A Bonferroni correction was applied
to the a priori alpha level of 0.05 and was calculated
based on the number of individual models examined
for each of the SNPs on the adiponectin gene (0.05/24).
Therefore, a p-value threshold of 0.002 was used to de-
termine Bonferroni-corrected statistical significance for
ADIPOQ SNPs.
Pair-wise linkage disequilibrium (LD) and haplotype
blocks were assessed by Haploview (Broad Institute,
MA, USA) [31]. Haplotypes were analyzed using PLINK
association analysis for the identified haplotype blocks
using linear regression in PLINK. Haplotypes with esti-
mated frequency < 5 % were excluded from the analysis.
Global p-values are obtained by omnibus tests jointly es-
timating all haplotype effects and linear regression ana-
lysis was used for the individual haplotype association.
Results
General characteristics of the Jackson Heart Study
participants
The main characteristics of the study population dis-
aggregated by gender are presented in Table 1. Of
the 2968 self-identified African American participants,
1131 were men and 1837 were women. The presence
of overweight and obesity was significantly higher in
women compared to men (88.8 % vs. 82.6 %, p = 0.001).
Compared to men, women had significantly higher BMI
(30.0 vs. 33.3, p < 0.0001), total body fat content (29.6 %
vs. 43.3 %, p < 0.0001) and SAT (1721.9 units vs. 2687.5
units, p < 0.0001). Women also presented higher adipo-
nectin serum levels than men (6.04 μg/mL vs. 4.08 μg/mL,
p < 0.0001) and a higher proportion of annual household
income < $19,999 (32.13 % vs. 19.11 %), p < 0.0001). Com-
pared with women, men had higher VAT (903.7 cm3 vs.
948.1 cm3, p < 0.05) and PEA (17 % vs. 18 %, p = 0.006)
Table 1 Clinical and socio-demographic characteristics of the
study participants, stratified by gender
Variable Men (N = 1131) Women (N = 1837) p-value
Age (y) 53.75 ± 13.02 54.86 ± 12.73 0.022
Adiponectin (ug/mL) 4.08 ± 3.38 6.04 ± 4.46 < .0001
Height (cm) 177.5 ± 6.88 164 ± 6.50 < .0001
Weight (kg) 94.76 ± 21.70 89.54 ± 21.71 < .0001
BMI (kg/m2) 30.01 ± 6.33 33.26 ± 7.79 < .0001
Overweight/Obese 82.65 % 88.88 % < .0001
(BMI≥ 25)
WC (cm) 101.6 ± 15.42 101.1 ± 16.89 0.35
Waist-hip ratio 0.94 ± 0.06 0.87 ± 0.08 < .0001
Total body fat (%) 29.61 ± 7.96 43.26 ± 7.02 < .0001
Fat mass (kg) 64.89 ± 32.12 86.35 ± 34.34 < .0001
Total fat (cm3) 2670.0 ± 1051.2 3591.3 ± 1175.7 < .0001
VAT (cm3) 948.1 ± 425.3 903.7 ± 390.6 0.037
SAT (cm3) 1721.9 ± 794.3 2687.5 ± 964 < .0001
PEA mean (SD) 0.18 ± 0.09 0.17 ± 0.08 0.0068
Smoking (%) 17.94 % 11.07 % < .0001
Annual household
income:
≤ $19,999 19.11 % 32.13 % < .0001
$20,000-49,999 34.25 % 39.40 % < .0001
$50,000 ≥ 46.65 % 28.47 % < .0001
Data presented as mean ± SD. BMI body mass index, WC waist circumference,
SAT subcutaneous adipose tissue, VAT visceral adipose tissue, PEA Individual
Proportions of European Ancestry
Riestra et al. BMC Medical Genetics  (2015) 16:65 Page 4 of 12
as well as higher annual household income > $50,000
(46.65 % vs. 28.4 % p < 0.0001).
When comparing the subject characteristics in men and
women by obesity status, weight, WC, HC, WHR and
total body fat content, VAT and SAT were significantly
higher in obese men and women than in non-obese sub-
jects. Adiponectin levels were significantly lower in over-
weight and obese study participants compared to men and
women of normal weight (data not shown).
Associations between ADIPOQ SNPs and adiponectin
levels
Four variants were found to be nominally associated
after the Bonferroni correction (P < 0.002) with plasma
adiponectin levels adjusting for age, gender, BMI and
PEA (Additional file 1: Table S2) with p-values ranging
from 0.000579 to 3.28 × 10−6. The C allele of the SNP
rs7641507 showed the strongest association with higher
adiponectin levels (p = 3.28 × 10−6). The major alleles T
at SNP rs6444174, A at rs1403697, and G at rs16861205
were also significantly associated with increased adipo-
nectin concentrations. The SNPs rs6444174, rs1403697
and rs7641507 were located in the 3′-UTR and the
rs16861205 in the intron 1.
Given the significant gender differences in adiponec-
tin levels we also performed a sex stratified analysis to
test gender-specific differences in the effect of these
SNPs on serum adiponectin concentrations, as shown
in Tables 2 and 3. We found strong significant associa-
tions between the ADIPOQ SNPs rs6444174 (β 0.1617
(0.0402) p = 6.15 × 10−5), rs1403697 (β 0.1126 (0.0296)
p = 0.0001) and rs7641507 (β 0.1127 (0.0296) p = 0.0001)
and a marginal association of rs16861205 (p = 0.03) with
serum adiponectin levels after controlling for PEA, age,
BMI, annual household income and smoking in women
(Table 2). However, these associations were no longer sig-
nificant in men (Table 3).
Influence of genetic ancestry on the association of
ADIPOQ SNPs and obesity
We analyzed the relationship between ADIPOQ SNPs
and obesity in the group (Table 4) and found a signifi-
cant association between ADIPOQ SNP rs12495941 and
obesity (OR 2.3737 (0.2661) p = 0.001158). However the
significance of this relationship was lost following adjust-
ment for PEA suggesting a modulatory effect of PEA on
the association between this SNP and obesity. In order
to explore the influence of PEA on the association be-
tween ADIPOQ SNPs and obesity we stratified the ana-
lysis by PEA levels expressed in two categories (low vs.
high PEA) based on the median value of this variable
(15 %). As shown in Table 5 we observed that the
Table 2 Association between ADIPOQ SNPs and adiponectin serum levels in women from the Jackson Heart Study cohort
SNPs Model 1 Model 2 Model 3
rs Alleles β (SE) P value β (SE) P value β (SE) P value
rs4632532 T/C −0.064 (0.028) 0.023 −0.072 (0.03) 0.031 −0.083 (0.036) 0.023
rs6444174 T/C 0.13 (0.030) 0.000011 0.15 (0.037) 0.000018 0.16 (0.040) 0.000061
rs16861194 A/G 0.019 (0.023) 0.40 0.021 (0.028) 0.44 0.025 (0.031) 0.41
rs182052 G/A 0.019 (0.023) 0.42 0.020 (0.028) 0.48 0.022 (0.031) 0.48
rs710445 A/G 0.019 (0.023) 0.40 0.021 (0.028) 0.44 0.025 (0.031) 0.42
rs16861205 G/A −0.13 (0.036) 0.00031 −0.11 (0.042) 0.0086 −0.096 (0.046) 0.039
rs822394 C/A −0.064 (0.045) 0.15 −0.057 (0.055) 0.30 −0.035 (0.059) 0.55
rs12495941 G/T 0.13 (0.082) 0.089 0.0090 (0.11) 0.93 −0.072 (0.12) 0.55
rs7649121 A/T 0.045 (0.070) 0.51 0.066 (0.081) 0.41 0.031 (0.090) 0.73
rs7627128 C/A −0.014 (0.15) 0.92 −0.15 (0.19) 0.42 −0.073 (0.20) 0.72
rs9877202 A/G −0.049 (0.042) 0.24 −0.039 (0.051) 0.43 −0.024 (0.054) 0.65
rs1501299 G/T −0.14 (0.049) 0.0043 −0.11 (0.056) 0.042 −0.130 (0.059) 0.029
rs3821799 T/C 0.031 (0.028) 0.27 0.024 (0.033) 0.46 0.039 (0.036) 0.28
rs9842733 A/T −0.099 (0.11) 0.38 0.044 (0.13) 0.74 0.027 (0.150) 0.85
rs1403697 A/G 0.088 (0.022) 0.000095 0.10 (0.027) 0.00019 0.11 (0.029) 0.00015
rs7641507 C/T 0.088 (0.022) 0.000094 0.10 (0.027) 0.00019 0.11 (0.029) 0.00014
rs1403696 T/C −0.046 (0.081) 0.56 −0.0047 (0.10) 0.96 −0.098 (0.11) 0.40
rs13085499 T/C 0.093 (0.11) 0.41 0.088 (0.13) 0.51 −0.0023 (0.14) 0.98
Alleles listed as major/minor allele; Model 1: Adjusted for BMI, age, smoking; Model 2: adjusted for age, smoking, ancestry; Model 3: adjusted for age, smoking,
ancestry, BMI, annual household income: The results of the association are listed as the Beta (standard error) (β (SE)) with the corresponding P-value. β coefficients
represent the change in absolute trait values of each additional risk allele
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association between the G allele and obesity was present
in those individuals within the lower PEA group and this
p-value almost reached the Bonferroni p-value threshold
(p = 0.004) after adjusting for gender, age, and smoking.
Associations between ADIPOQ SNPs and obesity
phenotypes
Regarding the association between ADIPOQ polymor-
phisms and obesity phenotypes, none of the ADIPOQ
SNPs studied met the Bonferroni p-value thresholds for a
significant relationship with any of the adiposity measures
(WC, HC, VAT, SAT, TF) and BMI, after controlling for
age, smoking, PEA, and sex (data not shown). However as
shown in Table 6 in the analysis stratified by obesity cat-
egories (< 30 kg/m2 and ≥ 30 kg/m2), the presence of the
T allele of ADIPOQ rs6444174 was negatively associated
with BMI (β = -0.0417 (0.0115) p = 0.0003662) but only in
those participants with normal weight after adjusting for
age, sex, smoking, PEA, and annual household income.
This result provided evidence of an effect modification by
the obesity status of the association between ADIPOQ
rs6444174 and BMI. Using a Chi-square test, we com-
pared the genotype distribution of ADIPOQ rs6444174
polymorphism in normal-weight with their distribu-
tions in overweight/obese participants. No differences
in genotype or allelic distributions among obesity cat-
egories were observed (data not shown).
Associations of common haplotype with adiponectin
levels and obesity
The linkage disequilibrium plot for the ADIPOQ variants
selected in this study is presented in Fig. 1. Two haplo-
type blocks were identified in ADIPOQ among African
Americans from the JHS cohort.
In order to study the combined effect of the ADIPOQ
SNPs in the present study, we tested the association of
those SNPs that were significantly associated with adipo-
nectin levels. The four SNPs significantly associated with
adiponectin levels in woman are located in the same LD
block (Fig. 1). Considering all of the four SNPs simul-
taneously and using age, sex and BMI and PEA as covar-
iates the haplotype analysis predicted three common
haplotypes (frequency > 5 %). The most probable haplo-
type (CGGT) had an estimated global frequency of 44 %.
To assess the association with adiponectin levels, we
performed a global test of association across all haplo-
types, as well as haplotype-specific association by linear
regression analysis.
As shown in Table 7, the haplotype frequencies were
not different in men and women for the three mayor
Table 3 Association between ADIPOQ SNPs and adiponectin serum levels in men from the Jackson Heart Study cohort
SNPs Model 1 Model 2 Model 3
rs Alleles β (SE) P value β (SE) P value β (SE) P value
rs4632532 T/C −0.048 (0.038) 0.21 −0.054 (0.044) 0.22 −0.041 (0.047) 0.37
rs6444174 T/C 0.034 (0.040) 0.39 0.054 (0.045) 0.22 0.042 (0.048) 0.38
rs16861194 A/G 0.069 (0.032) 0.032 0.080 (0.036) 0.027 0.083 (0.038) 0.029
rs266729 C/G −0.039 (0.042) 0.35 −0.025 (0.048) 0.59 −0.022 (0.051) 0.67
rs182052 G/A 0.073 (0.032) 0.024 0.083 (0.036) 0.024 0.090 (0.039) 0.020
rs710445 A/G 0.070 (0.032) 0.027 0.082 (0.036) 0.022 0.086 (0.038) 0.024
rs16861205 G/A −0.084 (0.050) 0.093 −0.147 (0.057) 0.010 −0.11 (0.061) 0.074
rs822394 C/A −0.075 (0.062) 0.22 −0.126 (0.070) 0.071 −0.109 (0.07) 0.14
rs12495941 A/G −0.047 (0.13) 0.72 −0.092 (0.15) 0.56 −0.16 (0.16) 0.32
rs7649121 G/T 0.046 (0.090) 0.60 0.082 (0.11) 0.45 0.095 (0.11) 0.39
rs7627128 A/T −0.17 (0.19) 0.36 −0.15 (0.26) 0.55 −0.37 (0.28) 0.18
rs9877202 C/A −0.077 (0.057) 0.18 −0.10 (0.063) 0.099 −0.10 (0.067) 0.13
rs1501299 A/G −0.019 (0.062) 0.76 −0.063 (0.071) 0.37 −0.11 (0.078) 0.15
rs3821799 G/T 0.036 (0.038) 0.34 0.025 (0.043) 0.56 0.023 (0.046) 0.62
rs1403697 C/T 0.084 (0.030) 0.0063 0.097 (0.034) 0.0051 0.105 (0.037) 0.0048
rs7641507 A/T 0.084 (0.030) 0.0063 0.097 (0.034) 0.0051 0.105 (0.037) 0.0048
rs1403696 A/G 0.079 (0.146) 0.58 0.15 (0.16) 0.37 0.071 (0.15) 0.63
rs13085499 C/T 0.278 (0.162) 0.086 0.31 (0.21) 0.13 0.283 (0.21) 0.19
Alleles listed as major/minor allele; Model 1: Adjusted for BMI, age, smoking; Model 2: adjusted for age, smoking, ancestry; Model 3: adjusted for age, smoking,
ancestry, BMI, annual household income. The results of the association are listed as the beta (standard error) (β (SE)) with the corresponding P-value. β Coefficients
represent the change in absolute trait values of each additional risk allele
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haplotype combinations (CGGT/CAAC/CGAC). The
haplotype analysis revealed significant associations with
adiponectin levels for the four SNPs haploblock CAAC
in women but not in men (global p = 0.0006 vs. 0.026).
After adjustment for PEA, annual household income,
BMI and smoking these results were consistent with the
gender effect observed in the individual SNP analyses.
The haplotype CGGT was associated with increased adi-
ponectin levels (0.00029) while the CGAC haplotype
showed the opposite effect (0.001).
Discussion
In the present study, we examined the relationship between
ADIPOQ polymorphisms and adiponectin levels and obes-
ity phenotypes in African American participants from the
JHS. The ADIPOQ gene has been found to be strongly
associated with obesity and serum adiponectin levels among
numerous study populations [2, 3, 10, 12, 15, 32, 33]. Our
study attempted to confirm some of these findings. We
evaluated whether ADIPOQ SNPs are associated with adi-
ponectin levels and obesity phenotypes in a large popula-
tion sample of African American men and women. We
analyzed a high number of ADIPOQ SNPs, some of which
have been studied in other ethnic groups [34, 35], in order
Table 4 Association between ADIPOQ SNPs and obesity in the Jackson Heart Study cohort
SNPs Model 1 Model 2 Model 3 Model 4 Model 5
rs Alleles OR (SE) P value OR (SE) P value OR (SE) P value OR (SE) P value OR (SE) P value
rs4632532 T/C 1.033(0.10) 0.76 1.12 (0.12) 0.35 1.16 (0.13) 0.27 1.12 (0.12) 0.35 0.99 (0.10) 0.95
rs6444174 T/C 0.83 (0.11) 0.12 0.79 (0.14) 0.10 0.86 (0.15) 0.32 0.77 (0.14) 0.081 0.82 (0.11) 0.11
rs16861194 A/G 0.90 (0.091) 0.27 0.93 (0.10) 0.52 0.89 (0.11) 0.32 0.94 (0.10) 0.57 0.92 (0.090) 0.38
rs182052 G/A 0.90 (0.092) 0.29 0.94 (0.10) 0.60 0.90 (0.11) 0.38 0.95 (0.10) 0.66 0.93 (0.091) 0.43
rs710445 A/G 0.90 (0.091) 0.28 0.93 (0.10) 0.54 0.89 (0.11) 0.34 0.94 (0.10) 0.59 0.92 (0.090) 0.40
rs16861205 G/A 1.16 (0.13) 0.25 1.24 (0.15) 0.15 1.22 (0.17) 0.22 1.25 (0.15) 0.14 1.16 (0.13) 0.25
rs822394 C/A 1.05 (0.17) 0.75 1.10 (0.20) 0.62 1.09 (0.21) 0.60 1.10 (0.20) 0.62 1.04 (0.17) 0.80
rs12495941 G/T 2.37 (0.26) 0.0011 1.95 (0.36) 0.068 1.93 (0.39) 0.095 1.99 (0.37) 0.063 2.60 (0.26) 0.00028
rs7649121 A/T 0.95 (0.26) 0.87 0.93 (0.31) 0.83 1.12 (0.32) 0.70 0.95 (0.31) 0.89 0.95 (0.26) 0.85
rs7627128 C/A 0.38 (0.68) 0.16 1.19 (0.71) 0.80 1.61 (0.71) 0.50 1.18 (0.72) 0.81 0.37 (0.69) 0.16
rs9877202 A/G 1.03 (0.15) 0.82 1.04 (0.18) 0.81 1.01 (0.20) 0.95 1.04 (0.18) 0.81 1.04 (0.15) 0.77
rs1501299 G/T 1.33 (0.17) 0.091 1.35 (0.19) 0.11 1.28 (0.21) 0.25 1.35 (0.19) 0.12 1.27 (0.16) 0.15
rs3821799 T/C 0.88 (0.11) 0.28 0.84 (0.13) 0.20 0.79 (0.144) 0.11 0.83 (0.13) 0.18 0.88 (0.11) 0.28
rs9842733 A/T 1.71 (0.40) 0.18 2.19 (0.45) 0.086 2.32 (0.500) 0.091 2.37 (0.46) 0.060 1.88 (0.40) 0.11
rs1403697 A/G 0.87 (0.086) 0.13 0.88 (0.10) 0.22 0.89 (0.12) 0.3115 0.87 (0.10) 0.19 0.88 (0.085) 0.16
rs7641507 C/T 0.87 (0.086) 0.13 0.88 (0.10) 0.22 0.89 (0.11) 0.3125 0.87 (0.10) 0.19 0.88 (0.085) 0.16
rs1403696 T/C 0.69 (0.38) 0.34 0.64 (0.47) 0.36 0.51 (0.58) 0.2554 0.68 (0.47) 0.43 0.75 (0.38) 0.46
rs13085499 T/C 1.08 (0.42) 0.84 1.26 (0.50) 0.64 1.47 (0.54) 0.4686 1.37 (0.51) 0.53 1.26 (0.42) 0.57
Model 1: no adjustment; Model 2: adjusted for age, smoking; Model 3: adjusted for age, smoking, PEA; Model 4: adjusted for age, smoking, PEA, annual household
income, model 5: adjusted for age, smoking, PEA, sex. The results of the association are listed as OR (standard error) (OR (SE)) with the corresponding P-value
Table 5 Association between the rs12495941 ADIPOQ SNP and
obesity risk in participants with high and low PEA from the JHS
High PEA Low PEA
OR (SE) P value OR (SE) P value
Model 1 0.96 (0.5842) 0.94 −0.044 (0.16) 0.78
Model 2 −0.042 (0.1575) 0.78 4.33 (0.53) 0.0056
Model 3 −0.0050 (0.1487) 0.97 4.71 (0.54) 0.0042
Model 1: no adjustment; Model 2: adjusted for age, smoking, Model 3: adjusted
for age, smoking, sex, annual household income. The results of the association
are listed as OR (standard error) (OR (SE)) with the corresponding P-value
Table 6 Association between the rs6444174 ADIPOQ SNP and
BMI in normal weight and overweight or obese men and
women from the Jackson Heart Study cohort
Normal-weight Overweight/Obese
β (SE) P value β (SE) P value
Model 1 −0.019 (0.0095) 0.036 −0.0048 (0.0078) 0.53
Model 2 −0.020 (0.0095) 0.032 −0.0049 (0.0077) 0.52
Model 3 −0.035 (0.010) 0.0010 −0.0033 (0.0095) 0.72
Model 4 −0.041 (0.011) 0.00028 −0.0048 (0.0078) 0.53
Model 5 −0.034 (0.010) 0.0017 −0.0057 (0.0092) 0.54
Model 6 −0.041 (0.011) 0.00036 0.0021 (0.010) 0.83
Model 1: no adjustment; Model 2: adjusted for age, smoking; Model 3: adjusted
for age, smoking, PEA; model 4: adjusted for age, smoking, PEA, annual
household income, model 5: adjusted for age, smoking, PEA, sex. Model 6:
Adjusted for sex age, gender, smoking, annual household income and PEA.
The results of the association are listed as the beta (standard error) (β (SE)) with
the corresponding -value. β Coefficients represent the change in absolute traits
values of each additional risk allele
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to capture almost all the known common variability in this
gene.
There is growing evidence that ADIPOQ variants are
related to adiponectin levels and adiposity phenotypes.
ADIPOQ SNPs genotype frequencies and LD patterns vary
widely among ethnic groups and may explain in part the
differences in obesity prevalence between non-Hispanic
White and African Americans in the U.S. However, SNPs
in the ADIPOQ gene, have been almost exclusively exam-
ined in relation to these variables in European-derived or
Asian populations and the few studies conducted in
African Americans were small [36] or did not control for
population structure using Ancestry Informative Markers
(AIMS) as an accurate measure of population stratification.
In this study we found strong novel associations between
four ADIPOQ polymorphisms (rs6444174, rs16861205,
rs1403697, and rs7641507) and adiponectin levels in
African American women that were consistent with the
haplotype analysis. These associations remained significant
after adjustment for PEA, age, BMI, annual household
income and smoking. We also found that the ADIPOQ
rs6444174 variant was associated with BMI among normal
weight subjects. In addition, we observed that the associ-
ation between the rs12495941 and obesity risk appears to
Fig. 1 Linkage disequilibrium plot for SNPs in the ADIPOQ gene. The value within each diamond is R2 between pairs of SNPs. The red to white
gradient reflects higher to lower linkage disequilibrium values (red, high; white, low). Most common haplotype blocks codes and their frequencies in
women are indicated
Table 7 Association between the most common haplotype combinations in the ADIPOQ gene and adiponectin levels
Men Women
Haplotype F P value* (individual) P value (global) P value* (global) F P value* (individual) p P*
2222 CGGT 0.477 0.0114 0.45 0.00029
2111 CAAC 0.207 0.627 0.044 0.026 0.197 0.513 0.000258 0.000674
2211 CGAC 0.341 0.0245 0.348 0.001
Linear regression analysis was used for the individual haplotype association test. Global P values refer to the global test of association across all detected
haplotypes. p-value*: adjusted for PEA, annual household income, smoking, BMI and age
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be modulated by PEA, so that the association between the
G allele and a higher risk of obesity was present in those
individuals within the lower PEA.
Serum Adiponectin levels and ADIPOQ gene single
nucleotide polymorphisms
We found that the ADIPOQ variants rs6444174,
rs16861205, rs1403697, and rs7641507 were strongly
associated with baseline serum adiponectin levels in a
gender dependent manner. Our results showed that
the association of ADIPOQ polymorphisms with adi-
ponectin levels only remained significant in woman.
To the best of our knowledge, the wide sample size of
the JHS cohort, permitted for the first time, an exam-
ination of this association using a gender stratified
analysis in African Americans. These results are con-
sistent with prior GWAS studies that pinpointed the
ADIPOQ locus as the primary signal for plasma adipo-
nectin levels [12, 37], thus likely the primary source of
common variants influencing adiponectin level varia-
tions in different populations [13].
Regarding the ADIPOQ SNP rs6444174, we detected a
novel and significant sex specific association of this poly-
morphism with serum adiponectin levels. We also found
that this ADIPOQ variant appears to be related to BMI
only in normal weight subjects, and this association was
not significant in obese or overweight subjects sug-
gesting an obesity-gene interaction. However, we did not
find any direct association of this SNP with other obesity
phenotypes. Interestingly based on the ALlele FRE-
quency Database (ALFRED http://alfred.med.yale.edu/.)
the ancestral (T) allele of the rs6444174 SNP predomi-
nates in European populations where it is almost fixed
(100 %), whereas the derived (C) allele is exclusive to Af-
rican populations (98.7–100 %). Several studies have
reported a significant association between BMI and dif-
ferent ADIPOQ SNPs [38–40]. However, much of this
literature has been inconclusive while other studies have
failed to find any associations [7, 41, 42]. To our know-
ledge, hardly any data exists in the literature regarding
the influence of this particular ADIPOQ SNP on adi-
ponectin levels or obesity phenotypes. A recent study
conducted in Saudi population showed this SNP to be
associated only with low HDL-C serum levels. Although
the authors did not report the rare allele frequency for this
polymorphism in their population [43], demographic data
from Saudi Arabia shows 10 % of Afro-Asian ancestry
which could explain the presence of this allele in this
ethnic group. We hypothesized that this African ancestry-
specific allele might be conferring a metabolic protection
through higher adiponectin levels and an increased
homeostasis of fat deposition in subjects within a normal
weight range but that protection or metabolic advantage is
susceptible to modification under an obese environment.
A study conducted by Rokholm et al [44] found that genes
related to body fatness are expressed in a detrimental
manner under obesogenic environments. Until now the
focus has primarily been on physical activity with the fat
and carbohydrate intake as the main modifiers of the gen-
etic effect on adiposity [33, 45]. However, the presence of
obesity now represents the main effect modifier. Although
this polymorphism is located in the 3′-UTRT non-coding
gene region, we postulated that the underlying biology
behind the signal was likely to impact gene expression
through some obesity mediated regulatory mechanism.
For the rs16861205 ADIPOQ SNP variant, we found
that the A allele of this SNP was positively correlated
with adiponectin levels. However, in this case, the associ-
ation did not reach the Bonferroni significance threshold
in the gender-stratified analysis. To date only two stud-
ies have described similar associations. In one of the
studies conducted in a Finnish cohort [46], the authors
reported an association between the A allele and higher
adiponectin levels and lower basal body weight while
the other study conducted in Chinese population re-
ported that the AA genotype acts as a protective factor
against metabolic syndrome [47]. This polymorphism is
an intronic variant, although introns are non-coding re-
gions. There is evidence that intron-derived miRNAs
can suppress intracellular RNA homologues and regu-
late the gene function by repressing translation or cleav-
ing RNA transcripts [48]. Another possibility is that this
SNP, would be a marker in linkage disequilibrium with a
functional variant.
When analyzing the rs1403697 ADIPOQ polymorph-
ism we also found a strong sex-specific association be-
tween the major allele A and adiponectin levels. Women
carriers of the A allele presented significantly higher
plasma adiponectin concentrations. To our knowledge
this represents a novel finding because none of the pre-
vious studies conducted in different populations including
African Americans have found an association between this
polymorphism and adiponectin levels [17, 49].
In this study we also identified a novel association be-
tween the ADIPOQ rs7641507 polymorphism and adipo-
nectin levels. The frequency of the minor allele in our
population was 5 %, similar to what is described for YRB
HAPMAP population but, interestingly, this polymorph-
ism appears to be fixed in JPT CHB and CEU HAPMAP
populations. There is almost no literature regarding the
association between this polymorphism and adiponectin
levels probably because of its low frequency in many
ethnic groups. As an example, this variant was also
found to be monomorphic in Hispanics from the IRAS
Family study but not in African Americans [17].
With respect to the haplotype analysis, we found a co-
existence of two haplotypes with opposite genetic effects
in our population that is unique. In accordance with the
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genotype analyses, the haplotype consisting of the four
major alleles CGGT was positively associated with in-
creased serum adiponectin levels.
In summary, the ADIPOQ SNPs found to be associated
with adiponectin levels in women in this African American
cohort differ from those ADIPOQ SNPs that have been his-
torically associated with adiponectin levels in other popula-
tions. Examples include SNPs such as theG276T SNP in
intron 2 and the T45G in exon 2 [50] and other ADIPOQ
SNPs located at the promoter region and linked to a regu-
lation of the promoter activity [51, 52] [53], as well from
those SNPs reported in the scarce studies conducted in
African-American population [7, 16, 17, 34, 49] where only
the association between the promoter ADIPOQ variant
rs17300539 and adiponectin levels was consistent with
other studies conducted in individuals of European descent
[17, 52]. This inconsistency may be the result of the inclu-
sion of participants with different ethnic backgrounds, lack
of gender stratified analysis, control for population struc-
ture and smaller sample sizes.
This study is a good example of the important role
for sex-differentiated effects in the architecture of com-
plex traits. Gender can be considered a measured envir-
onmental risk factor which incorporates established
anatomical, physiological, and behavioral differences
between males and females [54]. The sexual dimorph-
ism in adiponectin levels is well stablished starting at
puberty possibly influenced by sexual hormones. The
assessment of the influence of sexual hormones and
menopause status on the relationship between ADIPOQ
SNPs and adiponectin concentrations, as well as the
possible hormone-SNP interactions which may explain
the observed gender differences in adiponectin levels
was beyond the scope of the current study. This rela-
tionship needs to be further evaluated in future studies
in African American who present lower adiponectin
levels compared to other ethnic groups.
Obesity phenotypes and ADIPOQ gene single nucleotide
polymorphisms
We found a statistically significant influence of PEA on
the association of the ADIPOQ rs12495941 SNP and
obesity. To the best of our knowledge, this is the first
time that a significant effect modification between ethni-
city and this ADIPOQ variant in determining obesity risk
is reported. In our population this ADIPOQ variant was
associated with an increased obesity risk but only in sub-
jects with a lower PEA or a higher percentage of African
ancestry. This finding is in line with a recent study in
the same African American cohort where the authors
found that the global proportion of European ancestry
was directly associated with adiponectin levels only in
normal weight and non-diabetic subjects. This suggest
an interplay between genetic and environmental factors
determining adiponectin levels where PEA acts as a pro-
tective factor which may explain ethnic differences in
obesity-related metabolic risk [55]. The studies analyzing
the association between this polymorphism and adiponec-
tin levels and obesity phenotypes are scarce and yielded dis-
parate results. In Hispanics from the IRAS study, this
polymorphism was associated to fasting glucose and SAT
but not in African Americans probably due to a sample size
of only 560 subjects [17]. The minor allele of this SNP was
also strongly associated with higher adiponectin levels in
Chinese participants from the Hong Kong Cardiovascular
Risk Factor Prevalence Study (CRISPS) [56]. Also in
Chinese population a significant association of this variant
and adiponectin levels has been reported [57]. However
the Framingham Heart Study did not find any association
between this SNP and plasma adiponectin levels [52]. Al-
though this ADIPOQ variant is a silent polymorphism
located in intron 1, and based on reports from the Alibaba
2.1 program, it is not involved in any putative transcrip-
tion binding site [58]. It has recently been suggested that
some organisms possess the ability to selectively use cer-
tain codons for transcriptional selection or translational
and RNA stability [43], conferring this SNP a potential
regulatory activity.
Our research presents some strengths and limitations.
The fact that the sample size far exceeds previous stud-
ies, permitted us to capture most of the variation across
the adiponectin gene in African Americans through a
tag-SNP approach rather than a small candidate SNP
selection. This is especially relevant to capture specific
association signals, particularly in populations with low
levels of LD like African Americans. In addition, we have
corrected the population stratification with an exhaust-
ive control for genetic ancestry based on AIMs. On the
other hand, besides the cross-sectional design of our
study, we did not incorporate food and nutrient intake,
physical activity, and other environmental covariates. In
addition, rare ADIPOQ variants are increasingly found
to be associated with serum adiponectin levels and have
previously been identified as contributors to adiponectin
variations in African Americans [17]. We did not include
these variants in our report.
It will be necessary to replicate these findings in other
unrelated, large and well characterized populations using
correct accounting for the genetic ancestry effects.
Conclusions
In summary, by using a tag-SNP approach we have com-
prehensively analyzed the association of genetic variants
and haplotypes of ADIPOQ with adiponectin levels and
obesity phenotypes in a large and well-characterized
phenotypically African American cohort. We found that
variants in the ADIPOQ gene are associated with adi-
ponectin levels in a gender dependent way. We also
Riestra et al. BMC Medical Genetics  (2015) 16:65 Page 10 of 12
observed that the association between ADIPOQ variants
and obesity risk and BMI seem to be modulated by other
factors such as PEA and obesity status, which suggests
that the effects of these polymorphisms are subject to a
strong interaction with genetic and environmental fac-
tors in the African American population. Interestingly
three of the variants related to increased adiponectin
levels were monomorphic or rare in other populations
conferring this variant’s a potential cardio-metabolic
protection in subjects with an African ancestry descent.
These findings indicate that African Americans may
truly have a unique genetic architecture of adiponectin
and obesity phenotypes related to the ADIPOQ gene.
Moreover, we detected variants and haplotypes for the
same gene modulating adiponectin levels in an antithetic
fashion, with some related to an increased serum adipo-
nectin and others related to decreased serum levels. This
phenomenon points to the complexity of polygenic traits
in which multiple alleles underlie the queried phenotype
and allele-specific effects contribute to both ends of the
phenotype. These observations, in conjunction with sex-
specific haplotype effects, highlight the challenge of
elucidating the genetic basis of polygenic diseases such
as obesity.
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